ADVANCE: DTG + FTC/(TAF or TDF) Noninferior to EFV/FTC/TDF in ART-Naive Patients in South Africa

July 21-24, 2019; Mexico City, Mexico
Phase III trial supports use of DTG-based regimens, with low rates of emergent resistance and no INSTI resistance.
Format: Microsoft PowerPoint (.ppt)
File Size: 250 KB
Released: July 29, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings